Q4 2025 Novartis AG Earnings Call Transcript
Key Points
- Novartis AG (NVS) achieved its 40% core margin goal two years ahead of schedule, demonstrating strong operational performance.
- The company reported an 8% increase in full-year sales and a 14% rise in Core Operating Income, showcasing robust financial growth.
- Key growth drivers such as KISQALI, KESIMPTA, SCEMBLIX, and PLUVICTO showed significant sales increases, with KISQALI growing by 57% and SCEMBLIX by 85%.
- Novartis AG (NVS) reached blockbuster status with LEQVIO and SCEMBLIX, indicating strong market acceptance and potential for continued growth.
- The company is on track for seven pivotal readouts in 2026, which could strengthen its mid-term outlook and drive future growth.
- Quarter four sales declined, impacted by gross-to-net adjustments and the loss of exclusivity for Entresto.
- The company expects low single-digit sales growth and a decline in core operating income for 2026, reflecting challenges from generic competition.
- The Avidity deal is anticipated to cause a 1% to 2% core margin dilution in 2026, affecting overall profitability.
- Novartis AG (NVS) faces significant generic impact in 2026, marking the largest patent expiration in its history.
- The company is navigating pricing challenges in the US due to the Most Favored Nation (MFN) rule, which could impact global launch strategies for key assets like Rhapsido and Ianalumab.
Good morning and good afternoon and welcome to the Novartis Q4 full-year 2025 results release conference call and live webcast. (Operator Instructions) A recording of the conference call, including the Q&A session, will be available on our website shortly after the call ends.
With that, I would like to hand over to Ms. Sloan Simpson, Head of Investor Relations. Please go ahead, madam.
Thank you, Sarah. Good morning and good afternoon, everyone, and welcome to our Q4 2025 earnings call. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors. These may cause actual results to be materially different from any future results, performance, or achievements expressed or implied by such statements. Please refer to the company's Form 20-F on file with the US Securities and Exchange Commission for a description of some of these factors.
The discussion today is not a solicitation of a proxy nor an offer
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
